JP2023535576A5 - - Google Patents

Info

Publication number
JP2023535576A5
JP2023535576A5 JP2023504517A JP2023504517A JP2023535576A5 JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5 JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5
Authority
JP
Japan
Application number
JP2023504517A
Other languages
Japanese (ja)
Other versions
JP2023535576A (ja
JPWO2022018171A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/070455 external-priority patent/WO2022018171A1/en
Publication of JP2023535576A publication Critical patent/JP2023535576A/ja
Publication of JPWO2022018171A5 publication Critical patent/JPWO2022018171A5/ja
Publication of JP2023535576A5 publication Critical patent/JP2023535576A5/ja
Pending legal-status Critical Current

Links

JP2023504517A 2020-07-23 2021-07-21 eEF1A2の遺伝子治療ベクターおよびその使用 Pending JP2023535576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055775P 2020-07-23 2020-07-23
US63/055,775 2020-07-23
PCT/EP2021/070455 WO2022018171A1 (en) 2020-07-23 2021-07-21 GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2023535576A JP2023535576A (ja) 2023-08-18
JPWO2022018171A5 JPWO2022018171A5 (https=) 2024-07-30
JP2023535576A5 true JP2023535576A5 (https=) 2024-07-30

Family

ID=71786970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504517A Pending JP2023535576A (ja) 2020-07-23 2021-07-21 eEF1A2の遺伝子治療ベクターおよびその使用

Country Status (10)

Country Link
US (1) US20230330265A1 (https=)
EP (1) EP4185332A1 (https=)
JP (1) JP2023535576A (https=)
KR (1) KR20230039669A (https=)
CN (1) CN116171325A (https=)
AU (1) AU2021312320A1 (https=)
CA (1) CA3186700A1 (https=)
IL (1) IL299955A (https=)
MX (1) MX2023000995A (https=)
WO (2) WO2022017630A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021572A1 (en) 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
EP3697452A4 (en) 2017-10-16 2021-11-24 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS
BR112020020841A2 (pt) 2018-04-11 2021-01-19 Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus Composições e métodos para transplante de célulastronco
CA3096293A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Aavベクターを使用したプラコフィリン-2(pkp2)遺伝子治療
WO2026006785A2 (en) * 2024-06-28 2026-01-02 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187626C (en) 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
US7122350B2 (en) * 2003-12-12 2006-10-17 Zymogenetics, Inc. Methods for enhancing expression of recombinant proteins
WO2009012176A2 (en) 2007-07-14 2009-01-22 The University Of Iowa Research Foundation Methods and compositions for treating brain diseases
JP2013523776A (ja) 2010-04-02 2013-06-17 セレジーン インコーポレイテッド パーキンソン病および脳のドーパミン作動性ニューロンのその他の障害を処置する方法
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
IL248102B (en) 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
CA3019315A1 (en) * 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
WO2020014523A1 (en) * 2018-07-12 2020-01-16 Rocket Pharmaceuticals, Ltd. Gene therapy vectors for treatment of danon disease
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023535576A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)